戻る Agenda
The 2012 US Payer Landscape: Results from a Survey of Medical and Pharmacy Directors on Comparative Effectiveness Research
Session Chair(s)
Richard Alan Brook, MBA, MS
Head, Retrospective Analysis
The Jestarx Group, United States
This session will present the findings from an online survey of medical and pharmacy directors of US health plans, insurers, and pharmacy benefit managers (PBMs) that covered how comparative effectiveness research (CER) and evidence-based medicine (EBM) results are incorporated into a Pharmacy and Therapeutics (P&T) Committee’s decision-making process. The speakers will also provide a pharma and a US health plan perspective on partnering with health plans and payers to develop and disseminate EBM and CER information, challenges with communicating these results, and strategies to address these challenges.
Learning Objective : Define comparative effectiveness research (CER) and evidence-based medicine (EBM) terminology; Describe how the health care environment is creating the opportunity to better use CER and EBM; Identify managed care executives’ perceptions on CER and EBM use in coverage decision making today and in the future.
Speaker(s)
Medical and Pharmacy Directors' Views on CER and EBM
Richard Alan Brook, MBA, MS
The Jestarx Group, United States
Head, Retrospective Analysis
A Pharmaceutical Company's Perspective on CER and EBM
Kitty Rajagopalan, PHD, MS
Sunovion Pharmaceuticals Inc., United States
Vice President, Health Economics and Outcomes Research
Making CER and EBM Results Actionable: The Perspective of an Independent Evidence Review Organization
Daniel A. Ollendorf, PHD, MPH
Center for the Evaluation of Value and Risk in Health, United States
Director, Value Measurement & Global Health Initiatives